Personalis (NASDAQ:PSNL) Stock Price Down 10.7% - What's Next?

Key Points

• Personalis, Inc. experienced a significant stock price drop of 10.7%, closing at $9.18 after trading as low as $9.52.
• Analysts have mixed opinions on the stock, with one upgrade to a "hold" rating from Wall Street Zen and a reaffirmed "sell" rating from Weiss Ratings.
• The company reported a revenue of $17.20 million for the last quarter, missing analyst expectations of $20.12 million.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) dropped 10.7% during trading on Friday . The stock traded as low as $9.52 and last traded at $9.18. Approximately 421,678 shares were traded during trading, a decline of 60% from the average daily volume of 1,045,764 shares. The stock had previously closed at $10.28.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Wall Street Zen upgraded shares of Personalis from a "sell" rating to a "hold" rating in a research note on Saturday, September 20th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Personalis in a research report on Wednesday, October 8th. BTIG Research set a $6.00 price target on shares of Personalis in a research report on Wednesday, August 6th. Finally, HC Wainwright reissued a "buy" rating and issued a $8.50 price objective on shares of Personalis in a research note on Monday, September 8th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $7.42.

Personalis Stock Performance

The stock has a market cap of $774.62 million, a PE ratio of -6.81 and a beta of 1.83. The company's 50 day simple moving average is $5.95 and its 200 day simple moving average is $5.39.

Personalis (NASDAQ:PSNL - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%.The company had revenue of $17.20 million during the quarter, compared to analyst estimates of $20.12 million. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts expect that Personalis, Inc. will post -1.4 earnings per share for the current year.

Institutional Trading of Personalis

Large investors have recently added to or reduced their stakes in the stock. American Century Companies Inc. grew its position in shares of Personalis by 33.9% during the 1st quarter. American Century Companies Inc. now owns 67,377 shares of the company's stock valued at $236,000 after acquiring an additional 17,056 shares during the period. Trexquant Investment LP lifted its stake in Personalis by 455.0% in the first quarter. Trexquant Investment LP now owns 122,959 shares of the company's stock valued at $432,000 after purchasing an additional 100,804 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Personalis by 55.7% in the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company's stock valued at $998,000 after buying an additional 101,706 shares during the period. XTX Topco Ltd raised its stake in shares of Personalis by 147.0% in the first quarter. XTX Topco Ltd now owns 82,666 shares of the company's stock valued at $290,000 after buying an additional 49,197 shares during the period. Finally, ARK Investment Management LLC raised its stake in shares of Personalis by 6.1% in the first quarter. ARK Investment Management LLC now owns 7,188,197 shares of the company's stock valued at $25,231,000 after buying an additional 412,762 shares during the period. Hedge funds and other institutional investors own 61.91% of the company's stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.